ProCE Banner Activity

How I Manage Adherence Issues in Patients Receiving BCR-ABL1 Inhibitor Therapy for CML

Clinical Thought
Read this commentary from CML expert Neil P. Shah, MD, PhD, discussing the importance of adherence to BCR-ABL1 inhibitor therapy in patients with CML and the barriers to adherence and ways to overcome them.

Released: March 02, 2022

Expiration: March 01, 2023

Share

Faculty

Neil P. Shah

Neil P. Shah, MD, PhD

Assistant Professor
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Neil P. Shah, MD, PhD

Assistant Professor
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Neil P. Shah, MD, PhD, has disclosed that he has received funds for research support from Bristol-Myers Squibb.